M&A - Akari Therapeutics Plc

Form Type: NT 10-K

Filing Date: 2025-03-31

Corporate Action: Acquisition

Type: Update

Accession Number: 000095017025047872

Filing Summary: Akari Therapeutics, Plc is unable to file its Annual Report on Form 10-K for the year ended December 31, 2024 within the required time due to the need for additional time to complete financial statement procedures. The delay is primarily due to ongoing accounting for a business combination that occurred on November 14, 2024. The company is expected to file the Form 10-K within the extension period provided by Rule 12b-25. Anticipated changes in operating results will occur as the Form 10-K will reflect the results from the acquisition of Peak Bio, Inc., resulting in increased operating expenses and a net loss from merger-related and restructuring expenses. Significant developments include hiring key personnel and pipeline prioritization.